The Relationship Between XinKang-I and Chronic Heart Failure

Launched by DONGGUAN HOSPITAL OF TRADITIONAL CHINESE MEDICINE · May 5, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a traditional Chinese medicine called XinKang-I (XK-I) on patients with chronic heart failure (CHF). Chronic heart failure is a serious condition where the heart can't pump blood effectively, leading to symptoms like fatigue and shortness of breath. The trial aims to see if adding XK-I to standard Western medicine can improve patients' heart function and their ability to exercise. Researchers will recruit 110 adults aged 18 to 85 who have been diagnosed with CHF for more than three months and meet specific health criteria.

If you qualify for the study, you will receive treatment for eight weeks, either with just Western medicine or with both Western medicine and XK-I. During this time, doctors will monitor your heart function and how well you can walk and exercise. The study has received ethical approval, ensuring that it follows strict guidelines to protect participants' rights and safety. Results from this trial will be shared in medical journals and at conferences, contributing to our understanding of how traditional Chinese medicine might help patients with heart failure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. History of CHF or clinical findings of CHF for more than 3 months. CHF was diagnosed in accordance with the European Society of Cardiology's 2021 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
• • 2. Patients ranged in age from 18 to 85.
• • 3. Cardiac function was graded at grade II-IV (New York Heart Association functional class).
• • 4. Patients who had not used traditional Chinese medicine for treating heart failure within 1 week before enrollment;
• • 5. Written informed consent will be obtained.
• Exclusion Criteria:
• • 1. acute cardiac insufficiency, acute myocarditis, severe valvular heart disease, malignant arrhythmia, obstructive cardiomyopathy, pericardial tamponade, constrictive pericarditis or acute coronary syndrome
• • 2. severe lung, liver or kidney dysfunction
• • 3. nervous and hematopoietic system
• • 4. malignant tumors
• • 5. hemodynamic nstability
• • 6. pulmonary embolism
• • 7. severe infection
• • 8. pregnant or lactating
• • 9. refusal to provide written informed consent for this study